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Abstract:  The effectiveness of photodynamic therapy is strongly dependent 
on the availabilty of oxygen. In the present paper we show that the ratio 
between photosensitiser phosphorescence and fluorescence is a parameter 
that can be used to monitor the competition between singlet oxygen 
production and other processes quenching the photosensitiser triplet state. 
We present a theoretical basis for the validity of this approach and a series 
of in vitro imaging experiments. 
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1. Introduction 
In recent years, dosimetry for clinical photodynamic therapy (PDT) has remained focused on 
the dosimetry of light and administered photosensitiser [1]. While state-of-the-art light 
dosimetry is critically important for limiting the light dose delivered to vulnerable areas of 
tissue it has been shown not to be a reliable predictor of therapeutic effect of PDT. This is 
because the photodynamic efficacy, expressed as the actual singlet oxygen production within 
the illuminated volume is determined by the local sensitiser concentration, the local fluence 
rate and the local concentration of ground state oxygen. The incorporation of these parameters 
is of vital importance for predictable and resproducible PDT. The concept of implicit 
dosimetry introduced by Wilson et al. [2] involves measuring various changing properties of 
the photosensitiser, such as the photobleaching rate constant, or triplet decay time, to 
determine the singlet oxygen production during PDT. Several possibilities for obtaining such 
signals during PDT have been investigated, with varying degrees of success. We have shown 
that for the photosensitiser aminolevulinic acid (ALA)-induced protoporphyrin (PpIX) the rate 
of photobleaching and tissue response increase with decreasing fluence rate [3] and the 
kinetics of photobleaching are influenced by light fractionation [4]. We have also shown that 
during oesophageal photodynamic therapy with ALA when in situ light dosimetry is used to 
standardise the fluence rate a wide range of photobleaching rates are observed [5]. Here the 
rate and extent of PpIX photobleaching is predictive of tissue response. The photobleaching of 
other photosensitisers has also been investigated. An in-vitro study using m-THPC [6] 
suggests that fluorescence photobleaching can be used as a predictor of PDT damage, 
however other investigators have reported more complex kinetics both in-vivo [7] and in 
different cellular compartments [8]. The relationship between mTHPC photobleaching and 
tissue response in-vivo is not yet clear. A system for measuring Photofrin photobleaching has 
recently been developed for the use in neurosurgery [9]. The photobleaching of Vertoporfin 
has also been investigated and Zeng et al. [10] have formulated a parameter that utilises the 
ratio of photoproduct to photosensitiser fluorescence to predict the response of tissues to PDT. 
A number of alternative dose metrics to fluorescence photobleaching have been investigated. 
Direct singlet oxygen luminescence measurements during PDT [11-13] as well as 
photosensitiser triplet decay time measurements in the time and frequency domain [14,15] 
have shown promising results but have all been difficult to reproduce clinically. Niedre et al. 
have recently shown that there is a direct relationship between singlet oxygen luminescence 
and cell kill in vitro [16]. A new method of monitoring PDT with the photosensitiser Pd-
Bacteriopheophorbide (TOOKAD) has recently been reported in which the palladium atom 
within the porphyrin ring provides MR contrast and allows oxygen partial pressures to be 
determined using BOLD contrast MRI [17].  
       What is clear from the work on implicit dosimetry published to date is that the 
appropriate technique is critically photosensitiser dependent and hence there remains a need 
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for alternative techniques for implicit dosimetry that can be applied in vivo. Even techniques 
that would not be practical for clinical use could still be of great value for experimental 
studies helping us reveal the many unanswered questions on the fundamentals of PDT. In the 
present paper we present the theoretical basis for the use of photosensitiser phosphorescence 
as a source of information for implicit dosimetry that is complementary to many of the other 
methods that have been developed, and an in vitro experiment to demonstrate its feasibility. 
2. Materials and methods 
2.1 Theoretical background 
Similar to that we have described previously [18], but with a term added to account for the 
phosphorescence, A20, the rate equations governing the population and depopulation of the 
ground, singlet and triplet states of the photosensitiser are: 
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where [N0(t)], [N1(t)] and [N2(t)] are the time dependent concentrations of the photosensitiser 
singlet ground state, the singlet excited state and the triplet ground state, Φ(t) is the fluence 
rate, Ai,j is the rate constant for the radiatiative and ki,j for the radiationless transition rates 
from state i to state j, q is the bimolecular quenching rate constant of the triplet state by 
ground state oxygen and [3O2(t)] the ground state oxygen concentration. Since we are dealing 
with relatively slow quasistatic changes in the populations (with respect to the transition rates) 
we can work with the equilibrium solution to Eq. (1): 
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where [N0], [N1] and [N2] stand for the equilibrium concentrations of singlet and triplet excited 
states and N00 stands for the total concentration of photosensitiser molecules. This step has 
further assumed that the fluence rates are far below saturation levels; i.e., no substantial 
depletion of the ground state population occurs, i.e., [N1] and [N2] << N00  [18]. The singlet 
oxygen production term can now be easily quantified as: 
[ ] [ ]232 OqNctionygen produSinglet Ox =
   (3) 
Quenching by oxygen is not the only mechanism of depopulation of the photosensitiser triplet 
state. Both spontaneous decay (decay rate k20) and phosphorescence (decay rate A20) are in 
direct competition with singlet oxygen production. We express this by a parameter α: 
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where α goes to zero at low levels of [3O2]. Alfa describes the fraction of the triplet state 
quenching events that lead to the production of singlet oxygen. Equation (4) clearly illustrates 
the underlying problem with the response of tissues to PDT: the effectiveness of PDT can be 
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reasonable at high tissue oxygen levels but goes to zero below a critical oxygen level. From 
Eq. (2) the steady state fluorescence (F) and phosphorescence (P) can be derived as: 
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The ratio of the 2 yields: 
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So, the signal defined by the ratio of phosphorescence and fluorescence is proportional to a 
constant γ multiplied by 1 minus the relative effectiveness of the treatment.  
2.2. Experiments 
Sn (IV) mesoporphyrin IX dichloride (SnMP; Frontier Scientific, Carnforth, UK) was 
dissolved in 1% albumin and excited using 408 nm radiation from an LED light source 
(Roithner, Vienna, AT). The variation in emission spectrum, acquired using a simple CCD 
spectrograph (Avantes, Eerbeek, NL.) with pO2 is shown in Fig. 1. Measurements were 
performed in a 10-mm pathlength quartz cuvette with a clear solution of 10 µg/l SnMP. 
Oxygen measurements were performed using a pO2 sensor needle (Unisense, Aarhus, DK). 
Emission below 600 nm is independent of pO2 and represents the fluorescence emission of 
SnMP. The peak centered on 716 nm is due to SnMP phosphorescence. 
       An imaging system consisting of a 2-stage peltier cooled slow scan CCD camera 
(Princeton Intruments Inc Princeton NJ, USA) equipped with a computer controlled filter 
wheel (Fairlight, Rotterdam, NL) and a f2.8/105 mm macro lens was used to acquire 
fluorescence and phosphorescence images from a quartz cuvette containing 10 µg/l SnMP. 
Camera, filter wheel and LED drivers were controlled by computer using LabView software. 
Two sets of filters were used, one for fluorescence detection (RG610 and BP635 ± 5 nm, 
Schott) and one for phosphorescence detection (RG 695). Excitation was performed using 408 
nm radiation from a cluster of 6 LEDs generating a homogeneous fluence rate of 5 mW cm-2 
at the side of the cuvette. A dark current image was taken before and after each image and the 
average subtracted.  
Fig. 1. Emission spectrum of 10 µg Sn-Mesoporphyrin in 1% albumin at different pO2 levels. 
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3. Results 
The measured phosphorescence/fluorescence ratio as a function of pO2 during illumination is 
shown in Fig. 2. The range of pO2 values was realised by measuring at different distances 
from the air-liquid interface in a thin (1x10x25-mm) cuvette imaged from the side. The 
oxygen sensor needle was moved in 100µm steps, and the Phosphorescence/fluorescence ratio 
determined just in front of needle.  
 
 
Figure 3 shows a sequence of images acquired from the bottom of the cuvette at 25 second 
intervals. In the upper left half of the image the pO2 level has dropped within the acquisition 
time of the first image (25 s) to a value low enough to induce substantial phosphorescence 
emission. Initially in the circular areas around the two small bubbles in the lower centre and 
left of the image the phosphorescence emission is lower because of oxygen diffusion from 
Fig. 3. (2.74 MB) Movie (100 frames, 25 seconds per frame) of the phosphorescence fluorescence 
ratio during PDT in a thin cuvette with a few airbubbles. The dark areas represent high oxygen 
levels, while the grey areas with increased phosphorescence indicate a decrease in oxygen levels. 
The bar refers to the value of α (eq.4); The total width of the image is 4.7 mm (size 1.28 Mb). 
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Fig. 2. Phosphorescence/fluorescence ratio as a function of the pO2 (left). Measurements were made in a 
cuvette using a 100 µm sensor needle positioned at different distances from the air-liquid interface (see 
ratio image on right). The curve is the best fit of eq.4 with a critical pO2 of 26 mm Hg (see discussion). 
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within each bubble. As the illumination progresses phosphorescence in this region gradually 
increases, as oxygen is depleted within each bubble. Around the larger bubble on the lower 
right the dark zone decreases in size, but does not disappear completely during the 2500 
seconds of the experiment.  
4. Discussion and conclusion 
The effectiveness of PDT is determined by the generation of sufficient cumulative amount of 
singlet oxygen throughout the treatment volume. This depends not only on sensitiser 
concentration and light fluence, but also on both the tissue vasculature and the oxygen 
diffusion distance; i.e., the action radius of PDT. As described by Foster et al. [19] this 
diffusion distance is an important parameter for PDT. The sequence of images in figure 3 
illustrates the PDT action radius. It shows the (dark) areas where the depletion of oxygen by 
consumption is compensated by diffusion from areas of high pO2. A similar situation occurs 
during PDT in vivo: i.e. an oxygen rich environment close to blood vessels and oxygen levels 
too low for effective PDT at more distant locations. The size of the PDT action radius depends 
on the vascular pO2,  the diffusion coefficient, fluence rate and the sensitiser concentration. 
The phenomena observed in this study closely follow the mathematical model presented by 
Foster et al. [19] who describe a direct relation between the size of the oxygenated zone and 
the pO2 inside a bloodvessel during PDT. If we assume an initial bubble pO2 of 120 mmHg 
we calculate that from the size of the bubble and the dark zone around an initial SnMP-PDT 
oxygen consumption rate of 12 µM/sec. This is of the same order of magnitude as found by 
Foster et al. who calculated 6 µM/sec for protoporphyrin IX. 
       In theoretical analysis for the in-vitro study presented, we have not considered the 
influence of tissue optical properties on the measured signals of fluorescence and 
phosphorescence that may occur when the technique is applied in-vivo. A positive side effect 
of the ratioing approach is that it compensates for the photobleaching of the photosensitiser 
during PDT. In addition, it cancels out the excitation fluence rate Φ from the equations and 
hence spatial variations in the excitation intensity or the absorption and scattering properties 
of the tissue at this wavelength will not influence the ratio image. A complicating factor in-
vivo is that the spectral separation between fluorescence and phosphorescence required to 
enable this measurement makes it unlikely that the escape functions at the phosphorescence 
and fluorescence wavelengths are identical. Hence, this part of the equation does not cancel 
out in the ratioing procedure. The importance of this effect will be dependent on the 
difference in emission wavelengths of phosphorescence and fluorescence and will be 
dependent on the particular photosensitiser used .  
       The study presented here was performed with SnMP, a commercially available 
photosensitiser that combines a high phosphorescence quantum yield with good spectral 
separation between fluorescence and phosphorescence. This is not a common feature of 
photosensitisers, in fact, only very few photosensitisers phosphoresce. These in vitro 
experiments have shown the feasibility of using the ratio of phosphorescence and fluorescence 
for treatment monitorring and we hope that it can encourage developers of new 
photosensitising agents to include the phosphorescent and fluorescent properties of the drugs 
in their evaluation. In fact, it is common practice to judge the suitability of a photosensitiser 
for PDT by properties like the absorption coefficient and the triplet quantum yield. The 
present study, however, indicates that for the evaluation of new photosensitisers the critical 
pO2, i.e the oxygen level at which the triplet quenching rate is matched by the spontaneous 
decay rate: 
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is important parameter to predict its possible clinical effectiveness.  
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